VB Spine has signed a definitive agreement with Augmedics to acquire the exclusive rights to the CT-Fluoro technology for spine applications.

The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.

The company has since learned the cyberattack was caused by a third-party contractor’s user session within its cloud-based system being compromised.

Funds will support Materna’s completion of a pivotal trial evaluating its system for reducing pelvic floor muscle injury during childbirth, as well as other commercial activities.

Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis.

OrthAlign has completed the first clinical procedures using its Lantern ASC system, designed for the ASC setting.

Aurenar’s V-Link system uses transauricular vagus nerve stimulation to modulate brain inflammation in patients that have experienced a stroke.

The initiative is designed to simplify the ability for GE HealthCare customers with existing interventional suites to access new technologies.

Hyperfine has commercially launched its next-generation Swoop portable MRI system (Model 2) in select European markets.

Medicina supplied devices bearing false CE markings to healthcare providers including National Health Service (NHS) Trusts across the UK.

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

Quest Diagnostics has received approval from the NYSDOH CLEP for its Haystack MRD test, expanding its use to cancer patients throughout the US.